Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, Gondo K, Yoshitake M, Noguchi K, Hino T
Second Department of Medicine, Kurume University School of Medicine, Japan.
Hepatology. 1993 Dec;18(6):1357-62.
Patients with hepatocellular carcinoma sometimes have erythrocytosis and high plasma erythropoietin levels. However, previous studies have not revealed direct evidence that the carcinoma cells produce the erythropoietin. To address this question, we carried out light and electron microscopic immunohistochemical studies, using a human erythropoietin antibody to the liver in three male patients with hepatocellular carcinoma and erythrocytosis. alpha-Feto-protein localization was also examined in serial liver sections by light microscopic immunohistochemistry with an antibody to alpha-fetoprotein. All three patients demonstrated high hemoglobin levels (16.7, 17.6 and 18.1 gm/dl) and high plasma erythropoietin levels (227, 266 and 280 mU/ml). In one patient the plasma erythropoietin level in the hepatic vein was significantly higher than that in the hepatic artery. The levels of plasma erythropoietin, as well as such tumor markers for hepatocellular carcinoma as serum alpha-fetoprotein and plasma des-gamma-carboxyprothrombin, were significantly reduced after treatment with an anticancer drug, cisplatin. Light microscopic immunohistochemistry showed that erythropoietin was definitely present in the cytoplasm of the hepatocellular carcinoma cells, but not in normal hepatocytes around the carcinoma lesion or in other nonparenchymal cells such as vascular endothelial cells and Kupffer cells. In electron microscopic immunohistochemistry, reaction products for erythropoietin were revealed in the cisternae of the endoplasmic reticulum in the carcinoma cells, suggesting the production of erythropoietin by these cells. Light microscopic immunohistochemistry showed that alpha-fetoprotein was localized in the hepatocellular carcinoma cells that were erythropoietin positive in the serial sections. These findings indicated that hepatocellular carcinoma cells produced erythropoietin as well as alpha-fetoprotein in these cases, leading to the complication of erythrocytosis.
肝细胞癌患者有时会出现红细胞增多症和血浆促红细胞生成素水平升高。然而,以往的研究尚未揭示癌细胞产生促红细胞生成素的直接证据。为了解决这个问题,我们对三名患有肝细胞癌和红细胞增多症的男性患者的肝脏进行了光镜和电镜免疫组织化学研究,使用人促红细胞生成素抗体。还通过用甲胎蛋白抗体进行光镜免疫组织化学在连续肝脏切片中检查甲胎蛋白定位。所有三名患者均表现出高血红蛋白水平(16.7、17.6和18.1克/分升)和高血浆促红细胞生成素水平(227、266和280毫国际单位/毫升)。在一名患者中,肝静脉中的血浆促红细胞生成素水平明显高于肝动脉中的水平。在用抗癌药物顺铂治疗后,血浆促红细胞生成素水平以及肝细胞癌的肿瘤标志物如血清甲胎蛋白和血浆去γ-羧基凝血酶原水平均显著降低。光镜免疫组织化学显示促红细胞生成素确实存在于癌细胞的细胞质中,但不存在于癌灶周围的正常肝细胞或其他非实质细胞如血管内皮细胞和库普弗细胞中。在电镜免疫组织化学中,在癌细胞内质网的池中发现了促红细胞生成素的反应产物,提示这些细胞产生促红细胞生成素。光镜免疫组织化学显示甲胎蛋白定位于连续切片中促红细胞生成素阳性的癌细胞中。这些发现表明,在这些病例中,癌细胞产生促红细胞生成素以及甲胎蛋白,导致红细胞增多症的并发症。